What we do

MRC Technology is the exclusive agent for the UK’s Medical Research Council and is responsible for translating cutting edge scientific discoveries into commercial products. We also protect IP for some of the world’s best academic organisations.

In addition we have small molecule drug discovery and therapeutic antibody facilities, providing lead stage therapeutic assets to pharmaceutical and biotechnology companies.

Partnering and licensing

MRC Technology adds value to cutting edge scientific discoveries through strategic patent protection and creative licensing of intellectual property (IP) or through partnered research with  MRC units and institutes (with an annual research budget of around US$ 530m/GBP£355). We also work with some of the world's other best academic organisations to develop their IP.

Small molecule drugs and therapeutic antibodies

Our Centre for Therapeutics Discovery (CTD) has been set-up to translate novel exciting biology into lead stage therapeutic assets with a clear pre-clinical and clinical developmental pathway. Bridging the gap between basic research and pre-clinical development, we develop innovative assays and pharma quality medicinal chemistry programmes from high quality hits.

Our Therapeutic Antibody Group (part of the Centre for Therapeutics Discovery), offers the chance to take advantage of its substantial antibody engineering know-how to target major life threatening and debilitating diseases.